tiprankstipranks
PTC Therapeutics Reports Strong Q3 2024 Performance
Company Announcements

PTC Therapeutics Reports Strong Q3 2024 Performance

PTC Therapeutics ( (PTCT) ) has released its Q3 earnings. Here is a breakdown of the information PTC Therapeutics presented to its investors.

Don't Miss our Black Friday Offers:

PTC Therapeutics, Inc. is a global biopharmaceutical company focused on developing and commercializing medicines for rare disorders, leveraging its scientific expertise and global infrastructure to provide access to transformative treatments.

In its latest earnings report, PTC Therapeutics announced a strong revenue performance for the third quarter of 2024, leading to an increase in full-year revenue guidance to $750-800 million. The company highlighted regulatory filings under review by the FDA and progress towards achieving its 2024 clinical and regulatory milestones.

Key financial highlights included total revenues of $196.8 million for the third quarter, driven by its DMD franchise, with Translarna and Emflaza contributing significantly. Notable clinical and regulatory achievements comprised NDA submissions for sepiapterin and Translarna, with further plans for a submission for vatiquinone. The company’s strategic focus was evident in its reduced R&D and SG&A expenses and improved cash position.

Looking forward, PTC Therapeutics remains on track to meet its 2024 objectives, supported by its robust financial position and strategic investments in its R&D programs. The company’s management maintains a strong outlook for continued growth and value creation for stakeholders.

Related Articles
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyPTC Therapeutics price target raised to $32 from $26 at Citi
TheFlyPTC Therapeutics price target raised to $71 from $47 at UBS
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App